• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4612468)   Today's Articles (12)   Subscriber (49383)
For: Danés I, Agustí A, Vallano A, Alerany C, Martínez J, Bosch JA, Ferrer A, Gratacós L, Pérez A, Olmo M, Marron SMC, Valderrama A, Bonafont X. Outcomes of off-label drug uses in hospitals: a multicentric prospective study. Eur J Clin Pharmacol 2014;70:1385-93. [PMID: 25196202 PMCID: PMC4198805 DOI: 10.1007/s00228-014-1746-2] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2014] [Accepted: 08/26/2014] [Indexed: 01/05/2023]
Number Cited by Other Article(s)
1
Meng M, Ge B, Lei W, Wu Y, Tian M, Lu Y, Shao T, Yang Y, Luo X, Luo J, Gao Y, Li Q, Chen Y. Paediatric off-label use of drugs in Gansu, China: a multicentre cross-sectional study. BMJ Open 2024;14:e078126. [PMID: 38740506 PMCID: PMC11097813 DOI: 10.1136/bmjopen-2023-078126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Accepted: 04/19/2024] [Indexed: 05/16/2024]  Open
2
Fontanals S, Esteve A, González A, Ibáñez C, Mesía R, Clopés A. Real-world treatment outcomes of immune checkpoint inhibitors used off-label in oncology: A comprehensive cancer institution experience. Pharmacol Res Perspect 2024;12:e1167. [PMID: 38193611 PMCID: PMC10775181 DOI: 10.1002/prp2.1167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 10/26/2023] [Accepted: 12/11/2023] [Indexed: 01/10/2024]  Open
3
Gross AJ, Pisano CE, Khunsriraksakul C, Spratt DE, Park HS, Sun Y, Wang M, Zaorsky NG. Real-World Data: Applications and Relevance to Cancer Clinical Trials. Semin Radiat Oncol 2023;33:374-385. [PMID: 37684067 DOI: 10.1016/j.semradonc.2023.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/10/2023]
4
Fontanals S, Esteve A, González A, Ibáñez C, Martínez J, Mesía R, Clopés A. Real-world treatment outcomes of medicines used in special situations (off-label and compassionate use) in oncology and hematology: A retrospective study from a comprehensive cancer institution. Cancer Med 2023;12:17112-17125. [PMID: 37496404 PMCID: PMC10501253 DOI: 10.1002/cam4.6360] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Revised: 06/17/2023] [Accepted: 07/09/2023] [Indexed: 07/28/2023]  Open
5
Sans-Pola C, Danés I, Bosch JÀ, Marrero-Álvarez P, Cortés J, Agustí A. Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity: a retrospective study and literature review. Front Med (Lausanne) 2023;10:1159794. [PMID: 37305139 PMCID: PMC10248418 DOI: 10.3389/fmed.2023.1159794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Accepted: 04/21/2023] [Indexed: 06/13/2023]  Open
6
Gasol M, Paco N, Guarga L, Bosch JÀ, Pontes C, Obach M. Early Access to Medicines: Use of Multicriteria Decision Analysis (MCDA) as a Decision Tool in Catalonia (Spain). J Clin Med 2022;11:jcm11051353. [PMID: 35268443 PMCID: PMC8910942 DOI: 10.3390/jcm11051353] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Revised: 02/21/2022] [Accepted: 02/24/2022] [Indexed: 01/13/2023]  Open
7
Sans-Pola C, Agustí A, Bosch JÀ, Agraz I, Alerany C, Danés I. Off-Label Use of Rituximab in Patients with Different Types of Nephropathies in a Tertiary Hospital: A Retrospective Study. J Clin Med 2021;10:4941. [PMID: 34768461 PMCID: PMC8584949 DOI: 10.3390/jcm10214941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Revised: 10/20/2021] [Accepted: 10/24/2021] [Indexed: 11/17/2022]  Open
8
Delate T, Hansen ML, Gutierrez AC, Le KN. Indications for Rituximab Use in an Integrated Health Care Delivery System. J Manag Care Spec Pharm 2020;26:832-838. [PMID: 32584674 PMCID: PMC10391100 DOI: 10.18553/jmcp.2020.26.7.832] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
9
Use of non-formulary high-cost medicines in an Australian public hospital. Int J Clin Pharm 2019;41:920-931. [PMID: 31161497 DOI: 10.1007/s11096-019-00853-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2018] [Accepted: 05/20/2019] [Indexed: 10/26/2022]
10
Omodeo P. Down-titration of omalizumab in a patient with chronic spontaneous urticaria. J DERMATOL TREAT 2018;29:12-13. [PMID: 30351196 DOI: 10.1080/09546634.2018.1529379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
11
Zeitoun JD, Ross JS, Atal I, Vivot A, Downing NS, Baron G, Ravaud P. Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study. BMJ Open 2017;7:e018587. [PMID: 29273664 PMCID: PMC5778291 DOI: 10.1136/bmjopen-2017-018587] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]  Open
12
Sicherheit und Wirksamkeitshinweise zum Off-label-Einsatz von Biologikatherapien nach Versagen konventioneller Therapien bei Patienten mit entzündlich rheumatischen Erkrankungen. Z Rheumatol 2017;77:28-39. [DOI: 10.1007/s00393-017-0330-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
13
El-Qutob D. Off-Label Uses of Omalizumab. Clin Rev Allergy Immunol 2016;50:84-96. [PMID: 26048266 DOI: 10.1007/s12016-015-8490-y] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
14
Calderazzo M, Rende P, Gambardella P, De Sarro G, Gallelli L. A Case of Interstitial Lung Disease Probably Related to Rituximab Treatment. DRUG SAFETY - CASE REPORTS 2016;2:8. [PMID: 27747720 PMCID: PMC5005575 DOI: 10.1007/s40800-015-0010-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
15
Levêque D. Off-label use of targeted therapies in oncology. World J Clin Oncol 2016;7:253-257. [PMID: 27081648 PMCID: PMC4826971 DOI: 10.5306/wjco.v7.i2.253] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/02/2015] [Revised: 10/23/2015] [Accepted: 01/04/2016] [Indexed: 02/06/2023]  Open
16
Hawcutt DB, Cooney L, Oni L, Pirmohamed M. Precision Dosing in Children. EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT 2016. [DOI: 10.1080/23808993.2016.1138845] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
17
Ghinea N, Lipworth W, Kerridge I. Off-Label Promotion of Prescription Medicine: Is It Ever Justifiable? Ther Innov Regul Sci 2015;49:359-363. [PMID: 30222394 DOI: 10.1177/2168479015570337] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
18
Salat D, Llop R, Aguilera C, Danés I, Bosch M, Asensio C, Castañeda F, Esterlich E, Vallano A. Therapeutic enquiries about biological agents as a tool to identify safety aspects and patterns of use. Eur J Hosp Pharm 2015;23:161-165. [PMID: 31156839 DOI: 10.1136/ejhpharm-2015-000770] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2015] [Revised: 09/22/2015] [Accepted: 10/12/2015] [Indexed: 12/12/2022]  Open
19
Sutherland A, Waldek S. It is time to review how unlicensed medicines are used. Eur J Clin Pharmacol 2015;71:1029-35. [PMID: 26153083 PMCID: PMC4532700 DOI: 10.1007/s00228-015-1886-z] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2015] [Accepted: 06/05/2015] [Indexed: 11/26/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA